Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | HMBS | P08397 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | DDO | Q99489 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4218270 | 0.86 | GRIA1 (0.34) | GRIA1GRIA2GRIA3GRIA4HMBS | |
| SCHEMBL1738125 | 0.82 | HMBS (0.46) | HMBSSPRKDM4EGAAPKM | |
| Hydrochloric Acid SCHEMBL5709777 | 0.80 | HMBS (0.43) | HMBSSPRKDM4EGAAPKM | |
| SCHEMBL20160825 | 0.78 | HMBS (0.42) | HMBSSPRKDM4EGAAPKM | |
| Hydrochloric Acid SCHEMBL5010692 | 0.77 | HMBS (0.40) | HMBSSPRKDM4EGAAPKM | |
| SCHEMBL26645662 | 0.77 | KDM4E (0.44) | HMBSSPRKDM4EGAAPKM | |
| SCHEMBL26359825 | 0.75 | HMBS (0.39) | HMBSSPRKDM4EGAAPKM | |
| SCHEMBL15973947 | 0.74 | GRIA1 (0.43) | GRIA1GRIA2GRIA3GRIA4DAO | |
| SCHEMBL22904635 | 0.74 | HMBS (0.37) | HMBSSPRKDM4EGAAPKM | |
| SCHEMBL19969546 | 0.71 | ERCC1 (0.46) | KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516889-B | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones | GLAXO GROUP LTD | 2013-07-31 | — | — | CN | disclosed |
| US-8071592-B2 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| CN-101516889-A | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | CN | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| US-4645766-A | 1,2-dihydro-2-oxo-3-hydroxymethyl pyridines, compositions and use | THE UPJOHN COMPANY (US) | 1987-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270374-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | ETFA, NQO2, GNAQ | GRIA1 4725/4885GRIA2 4694/4885GRIA3 4745/4885 |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | GRIA1 308/4885GRIA2 585/4885GRIA3 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.